Candriam Luxembourg S.C.A. raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 23.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,570 shares of the medical instruments supplier’s stock after acquiring an additional 17,652 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Becton, Dickinson and were worth $17,867,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Guardian Life Insurance Co. of America grew its position in Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after acquiring an additional 6 shares during the period. Wellington Shields & Co. LLC grew its position in Becton, Dickinson and by 0.3% in the second quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock valued at $496,000 after acquiring an additional 7 shares during the period. Parkside Financial Bank & Trust grew its position in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 9 shares during the period. Northstar Group Inc. grew its position in Becton, Dickinson and by 0.3% in the second quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock valued at $584,000 after acquiring an additional 9 shares during the period. Finally, North Star Investment Management Corp. grew its position in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after acquiring an additional 18 shares during the period. Hedge funds and other institutional investors own 87.42% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Candriam Luxembourg S.C.A. Has $17.87 Million Holdings in Becton, Dickinson and Company (BDX)” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://theolympiareport.com/2017/09/06/candriam-luxembourg-s-c-a-has-17-87-million-holdings-in-becton-dickinson-and-company-bdx.html.

BDX has been the topic of a number of analyst reports. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Finally, Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price objective for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and has an average rating of “Buy” and a consensus target price of $195.79.

In other news, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the sale, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,605 shares of company stock worth $9,718,986. Corporate insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) opened at 200.07 on Wednesday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The firm has a market cap of $45.53 billion, a price-to-earnings ratio of 57.94 and a beta of 1.06. The stock’s 50 day moving average price is $200.23 and its 200 day moving average price is $190.52.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. During the same quarter last year, the company posted $2.35 EPS. The company’s revenue for the quarter was down 5.1% compared to the same quarter last year. On average, equities research analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.46%. Becton, Dickinson and’s payout ratio is 83.43%.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.